Oncology

Understanding Chronic Lymphocytic Leukemia (CLL)

ID: 08035009

Understanding Chronic Lymphocytic Leukemia (CLL)

Understanding Chronic Lymphocytic Leukemia (CLL)
VN:RO [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)

Course Length:

  • 41 topics
  • 60 minutes of seat time

Language:

  • English

Course Features:

  • Audio narration
  • Animations
  • Progress checks
  • Pop quizzes
  • Final assessment

Target Audience:

  • Medical professionals
  • Medical students
  • Pharmaceutical representatives
  • Nurses

Description:

Leukemia is a type of cancer that originates in blood-producing organs, such as the bone marrow, and causes the uncontrolled proliferation of white blood cells. Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults in Western countries. This learning program is designed to introduce you to the main clinical features of CLL. The program begins with a brief overview of the classification of CLL, including a presentation of the hierarchy of lymphomas and the subtypes of CLL. You will then learn about the tools used to establish diagnosis and determine prognosis for CLL. You will also learn about the clinical management of CLL. As you progress through the program, you will also follow the case of Richard Ellis, a 71-year-old man suffering from CLL.

Upon completion of this learning program, you will be able to:

  • Define CLL and identify its 2 disease subtypes.
  • Describe the general epidemiology trends and risk factors for CLL.
  • Explain the tools used to establish diagnosis and determine prognosis for CLL.
  • Discuss the clinical management of CLL.
  1. WELCOME
    1. Disclaimer
    2. Navigation Instructions
    3. Introduction
    4. Learning Objectives
  2. PATHOLOGY AND CLASSIFICATION OF CLL
    1. Lymphomas
      • Hand icon: Hodgkin lymphoma
      • Hand icon: Non-Hodgkin lymphoma
    2. Chronic Lymphocytic Leukemia
      • Side note: Digging deeper
    3. Cellular Origins of CLL
      • Popup: Somatic hypermutation
      • Animated popup: CLL disease mechanism (Narrated)
    4. CLL Disease Subtypes
      • Hand icon: IgV-unmutated CLL
      • Hand icon: IgV-mutated CLL
    5. Pop Quiz
    6. Molecular Genetics of CLL
    7. Common Chromosomal Abnormalities in CLL
      • Popup: 13q deletion
      • Popup: 11q deletion
      • Popup: 17p deletion
      • Popup: Additional chromosome
  3. CASE STUDY
  4. EPIDEMIOLOGY
    1. Incidence of CLL
      • Popup: Age, gender, and race
      • Popup: Family history and genetic predisposition
    2. Progress Check
  5. CASE STUDY
  6. DIAGNOSIS AND PROGNOSIS OF CLL
    1. Overview
    2. Clinical Presentation and Differential Diagnosis
      • Popup: Clinical manifestation of other diseases
      • Side note: Digging deeper
    3. Peripheral Blood Tests
      • Popup: CLL cells under the microscope
    4. Pop Quiz
    5. Immunophenotyping and Flow Cytometry
      • Popup: Differential diagnosis with flow cytometry
    6. Fluorescence in situ Hybridization
    7. Bone Marrow Aspiration and Biopsy
      • Hand Icon: Bone marrow aspiration
      • Hand Icon: Bone marrow biopsy
    8. Staging
      • Popup: Rai system
      • Popup: Binet system
    9. Pop Quiz
    10. Prognostic Markers
      • Popup: IgV mutational status
      • Popup: CD38 immunophenotype
      • Popup: ZAP-70 expression
      • Popup: Chromosomal abnormalities
      • Popup: Levels of serum β-2 microglobulin and lymphocyte doubling time
    11. Clinical Complications
      • Hand Icon: Risk of infection
      • Hand Icon: Autoimmunity
      • Hand Icon: Transformation
      • Hand Icon: Secondary malignancies
    12. Progress Check
  7. CASE STUDY
  8. CLINICAL MANAGEMENT OF CLL
    1. Case Study and Overview
    2. Treatment Initiation
    3. Chemotherapy
      • Popup: Alkylating agents
      • Popup: Purine nucleoside analogs
      • Popup: Bifunctional agents
    4. Pop Quiz
    5. Immunotherapy
    6. Combination Therapies
      • Popup: Fludarabine, cyclophosphamide, and rituximab
      • Popup: Fludarabine and rituximab
      • Popup: Pentostatin, cyclophosphamide, and rituximab
      • Popup: Bendamustine and rituximab
    7. Supportive Care
    8. Pop Quiz
    9. Recurrent Disease
      • Popup: Relapsed and refractory patients
      • Popup: Additional cytogenetic abnormalities
    10. Progress Check
  9. TEST YOUR ACQUIRED KNOWLEDGE
    1. Summary
    2. Final Assessment
  10. END OF PROGRAM
  11. GLOSSARY
  12. REFERENCES



Return to catalog

Our Latest News

A.D.A.M. OnDemand™ is the most comprehensive library of off-the-shelf medical eLearning programs for patients, students, health care professionals and the pharmaceutical industry.
READ MORE
Whether you already have a learning management system (LMS) or need assistance hosting your programs, we can help you deliver and track training today!
READ MORE
A.D.A.M., the most credible source of health care information and multimedia visual learning assets for health care organizations, has the solutions you need to succeed in todays competitive...
READ MORE